Antiemetics
Key Points
Key Points
- The development of increasingly effective antiemetic regimens over the last quarter century has greatly reduced the incidence of nausea and vomiting due to chemotherapy.
- The recommended approach to preventing nausea and vomiting varies by the emetic risk of the treatment regimen.
- Adherence to antiemetic guidelines has been linked with improved control of nausea and vomiting.
- This update of the 2017 guideline adds guidance on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs).
Treatment
...reatmen...
Adult Pati...
...dult patients, the addition of a check...
...h-Emetic-Risk Antineoplastic Agen...
...treated with cisplatin and other high-emetic-r...
...ult patients treated with an anthracycline com...
Moderate-Emetic-Risk Antineopl...
...atients treated with carboplatin area under the...
...atients treated with moderate-emetic-risk a...
...ents treated with cyclophosphamide,...
...c-Risk Antineoplastic Agents...
...t patients treated with low-emetic-risk antineopla...
...Emetic Risk Antineoplastic Agents...
...reated with minimal emetic risk antineopla...
...lastic Combinations...
...reated with antineoplastic combinations shoul...
...nctive Drugs...
...orazepam is a useful adjunct to antiemetic drugs,...
...annabinoi...
...ence remains insufficient for a recommendation r...
...plementary and Alternative The...
...ains insufficient for a recommendation fo...
...gh-Dose Chemotherapy With Stem-Cell or Bone Mar...
...dult patients treated with high-dos...
...A four-drug combination of an NK1 receptor antag...
...Antineoplastic Therapy...
...dult patients treated with multiday antineoplasti...
...dult patients treated with 4- or 5-day ci...
...hrough Nausea and Vomiting...
...tients with breakthrough nausea or vomiting,...
...s who experience nausea or vomiting despite op...
...or dronabinol and nabilone ( IC , I , M )653...
...therwise ( IC , L , M )65...
Anticipatory Nausea and...
...ients should receive the most active antiemetic r...
...Emetic Risk Radiation T...
...patients treated with high-emetic-risk radi...
Moderate Emetic Risk Radiation The...
...tients treated with moderate-emetic-risk...
Low Emetic Risk Radiation Th...
...treated with radiation therapy to the brain s...
Minimal Emetic Risk Radiati...
...ients treated with minimal emetic risk radiati...
...iation and Antineoplastic Agent Therapy...
...tients treated with concurrent radiation...
...tric Patients...
...ic Risk Antineoplastic Age...
...tric patients treated with high-em...
...ted) Pediatric patients treated with high-em...
...dated) Pediatric patients treated with h...
...oderate Emetic Risk Antineoplastic A...
...nts treated with moderate-emetic-risk an...
...ric patients treated with moderate-emetic-risk an...
Low Emetic Risk Antineoplast...
...tric patients treated with low-emetic-risk antineo...
...al Emetic Risk Antineoplastic Age...
...atric patients treated with minimal e...
...ic Risk of Single Intravenous Antin...
...c Risk of Single Oral Antineoplastic Agent...
...3. Antiemetic Dosing for Adults by Chemothera...
...4. Emetic Risk in Adults by Site of Rad...
...etic Administration in Adults by Radiation Therapy...